AKUMS Q2 FY27 revenue rises 31.9% as EBITDA more than doubles

Akums Drugs and Pharmaceuticals Limited reported Q2 FY27 revenue of ₹1,342 crore, up 31.9% year on year, while EBITDA rose about 106% to ₹195 crore. The performance was led by its CDMO business, which generated ₹1,115 crore of revenue and recorded volume growth above 20% on a September MAT basis.

How did AKUMS perform in Q2 FY27?

AKUMS delivered higher revenue, operating profit and net profit in the quarter ended September 30, 2026. Consolidated revenue rose to ₹1,342 crore from ₹1,018 crore in Q2 FY26, representing growth of 31.9% year on year. Revenue was also up 15.1% sequentially.

EBITDA increased to ₹195 crore from ₹94 crore a year earlier. The company reported EBITDA growth of about 106% year on year and 11.5% quarter on quarter. This improvement lifted the EBITDA margin to 14.5% from 9.3% in the corresponding quarter of the previous financial year.

Profit after tax rose to ₹115 crore from ₹43 crore in Q2 FY26. The reported year-on-year increase in PAT was 168.3%, while the PAT margin stood at 8.4%. The results were announced on November 2, 2026, with an investor presentation and earnings-call recording subsequently made available.

What drove AKUMS revenue and EBITDA growth?

AKUMS attributed the operational momentum primarily to its contract development and manufacturing organisation, or CDMO, business. CDMO revenue reached ₹1,115 crore during Q2 FY27, up 38.6% from the year-earlier quarter and 15.6% from the preceding quarter.

The CDMO business accounted for the major part of the company's reported quarterly revenue. Its revenue growth was higher than the consolidated revenue growth rate, indicating that the segment was the principal contributor to the quarter's expansion based on the figures disclosed in the investor presentation.

The company also reported CDMO volume growth above 20% on a September MAT basis. The release did not provide a detailed product, customer or geography-wise split for this volume increase. It also did not provide management guidance for future quarters in the material provided.

How significant was the CDMO business contribution?

AKUMS generated approximately 83% of its Q2 FY27 revenue from CDMO operations, based on CDMO revenue of ₹1,115 crore and consolidated revenue of ₹1,342 crore. This makes the segment central to interpreting the company's reported quarterly performance.

CDMO businesses are linked to contract development and manufacturing work for pharmaceutical customers. For AKUMS, the disclosed 38.6% year-on-year rise in CDMO revenue was ahead of the 31.9% increase in overall revenue, while the reported volume growth above 20% provided an operational indicator alongside the revenue data.

The disclosed figures also show sequential momentum. CDMO revenue rose 15.6% quarter on quarter, marginally faster than the 15.1% sequential increase reported for consolidated revenue. The company did not disclose segment-level profitability in the information provided, so the precise contribution of CDMO to EBITDA cannot be separately determined.

What do the reported margins and PAT show?

AKUMS reported a 5.2-percentage-point expansion in EBITDA margin to 14.5% in Q2 FY27 from 9.3% in Q2 FY26. EBITDA increased by about ₹101 crore year on year, compared with a revenue increase of about ₹324 crore over the same period.

The rise in PAT was faster than both revenue and EBITDA growth. PAT increased by about ₹72 crore from the year-earlier quarter, reaching ₹115 crore. The PAT margin was reported at 8.4%, compared with an EBITDA margin of 14.5%.

For investors, the results provide reported evidence of higher operating profitability alongside revenue growth. However, the available presentation data does not specify the individual cost items, finance costs, tax factors or other line items that contributed to the change in net profit. Those details would be required to separately assess each driver of the PAT increase.

What disclosures accompanied the quarterly results?

AKUMS said the quarter covered unaudited financial results for the three months and half year ended September 30, 2026. The company submitted an investor presentation for Q2 FY27 and released the audio recording of its earnings conference call held on November 3, 2026.

The company stated that the earnings-call transcript would be submitted to stock exchanges and uploaded to its website in due course. The materials cited for the quarter therefore rely on the reported financial results and investor presentation rather than a published management-call transcript.

A November 2 announcement also stated that AKUMS acquired the Oriflame India business for ₹56 crore. The provided material does not set out further operational or financial details of that transaction, including its expected timing of consolidation or its contribution to future financial results.

Conclusion

AKUMS reported broad-based improvement in its Q2 FY27 financial metrics, with revenue rising 31.9%, EBITDA increasing about 106% and PAT growing 168.3% year on year. CDMO revenue of ₹1,115 crore, up 38.6%, was the principal disclosed driver of the quarter, while the increase in EBITDA margin to 14.5% showed improved operating profitability.

The next disclosure to watch is the company’s promised earnings-call transcript, which may provide additional detail on CDMO demand, operating-cost movements and the Oriflame India acquisition. Investors will also track whether the reported CDMO volume growth above 20% on a September MAT basis continues in subsequent quarterly results.